Logo

American Heart Association

  108
  0


Final ID:

Discussant: SCAN-MP

  • Alexander, Kevin  ( Stanford University , Palo Alto , California , United States )
  • Author Disclosures:
    Kevin Alexander: DO have relevant financial relationships ; Consultant:Arbor Biotechnologies:Active (exists now) ; Consultant:Bristol Myers Squibb:Past (completed) ; Consultant:Prothena:Active (exists now) ; Consultant:Novo Nordisk:Active (exists now) ; Consultant:Intellia:Past (completed) ; Consultant:Alnylam:Active (exists now)
Meeting Info:

Scientific Sessions 2024

2024

Chicago, Illinois

More abstracts on this topic:
Danon Disease Phase 1 RP-A501 Results: The First Single-Dose Intravenous Gene Therapy with Recombinant Adeno-Associated Virus (AAV9:LAMP2B) for a Monogenic Cardiomyopathy

Greenberg Barry, Coggins Matthew, Schwartz Jonathan, Rossano Joseph, Taylor Matthew, Colan Steven, Adler Eric, Ricks David, Yarabe Paul, Battiprolu Pavan, Shah Guarav, Patel Kinnari

Acoramidis Reduces All-Cause Mortality (ACM) and Cardiovascular-Related Hospitalization (CVH): Initial Outcomes From the ATTRibute-CM Open-Label Extension (OLE) Study

Judge Daniel, Masri Ahmad, Obici Laura, Poulsen Steen, Sarswat Nitasha, Shah Keyur, Soman Prem, Cao Xiaofan, Wang Kevin, Pecoraro Maria, Tamby Jean-francois, Gillmore Julian, Katz Leonid, Fox Jonathan, Maurer Mathew, Alexander Kevin, Ambardekar Amrut, Cappelli Francesco, Fontana Marianna, Garcia-pavia Pablo, Grogan Martha, Hanna Mazen

You have to be authorized to contact abstract author. Please, Login
Not Available